Get to know our clinical trials
Clinical trial with paclitaxel-carboplatin followed by niraparib maintenance compared to paclitaxel-carboplatin-bevacizumab followed by niraparib-bevacizumab maintenance in patients with advanced ovarian cancer after surgery.
THE OBJECTIVE OF THE STUDY IS TO EVALUATE WHETHER CARBOPLATIN-PACLITAXEL-BEVACIZUMAB* CHEMOTHERAPY FOLLOWED BY NIRAPARIB-BEVACIZUMAB* MAINTENANCE IMPROVES THE TREATMENT OF ADVANCED OVARIAN CANCER AFTER INITIAL COMPLETE SURGERY.
Technical Summary
- RANDOMIZED STUDY OF PACLITAXEL - CARBOPLATIN FOLLOWED BY MAINTENANCE WITH NIRAPARIB COMPARED TO PACLITAXEL - CARBOPLATIN - BEVACIZUMAB FOLLOWED BY MAINTENANCE WITH NIRAPARIB BEVACIZUMAB IN PATIENTS WITH ADVANCED OVARIAN CANCER AFTER FIRST-LINE COMPLETE CYTOREDUCTIVE SURGERY. IMMUNOTHERAPY.
- Code EudraCT: 2021-004278-76
- Protocol number: GINECO-OV129b/OV63
- Promoter: ARCAGY-GINECO
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.